In the original full paper, 1 Figure 2D, we have inadvertently uploaded an incorrect figure. We came across this error during the process of data archiving. However, the correction did not affect the quantification (Figure 2D) and therefore, the original interpretation of data and conclusions remain same. Corrected data are identified in red arrow below.
Figure 2D.
Representative image of MYOG of C2C12 myotubes transfected with shPdk4 or shControl and treated with or without dexamethasone (DEX) (100 μM) for 24 h. Quantification represents the levels of the MYOG + ve cell. n = 4; number of image capture sites 20 from each group. **P < 0.01; ***P < 0.001; ****P < 0.0001. Tukey's multiple comparisons test was used for the analysed.
Corrigendum to I.S. Sinam et al. J of Cachexia, Sarcopenia and Muscle, 13, 3122–3136. DOI: 10.1002/jcsm.13100. Journal of Cachexia, Sarcopenia and Muscle 2023, 14, 2455–2455
Reference
- 1. Sinam IS, Chanda D, Thoudam T, Kim MJ, Kim BG, Kang HJ, et al. Pyruvate dehydrogenase kinase 4 promotes ubiquitin–proteasome system‐dependent muscle atrophy. J Cachexia Sarcopenia Muscle 2022;13:3122–3136. [DOI] [PMC free article] [PubMed] [Google Scholar]